68Ga-PSMA-11 PET Represents the Tumoricidal Effect of 223Ra in a Patient With Castrate-Resistant Metastatic Prostate Cancer

    loading  Checking for direct PDF access through Ovid


A 64-year-old man with prostate cancer and an increasing prostate-specific antigen (PSA) level under therapy with abiraterone acetate underwent a therapy with 223Ra. Before the first therapy and 4 weeks after the last cycle, the patient underwent 68Ga-PSMA PET, which showed a clear response of bone metastases.

Related Topics

    loading  Loading Related Articles